PharmChem Inc
PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse. Its PharmChek Sweat Patch uses sweat as the source and offers alternative to urine testing for cocaine, opiates, amphetamines, PCP, and marijuana. The company was incorporated in 2000 and is based in Fort Worth, Texas.
PharmChem Inc (PCHM) - Net Assets
Latest net assets as of December 2024: $2.15 Million USD
Based on the latest financial reports, PharmChem Inc (PCHM) has net assets worth $2.15 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.73 Million) and total liabilities ($585.39K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.15 Million |
| % of Total Assets | 78.59% |
| Annual Growth Rate | -3.16% |
| 5-Year Change | -71.39% |
| 10-Year Change | -73.97% |
| Growth Volatility | 53.71 |
PharmChem Inc - Net Assets Trend (1989–2024)
This chart illustrates how PharmChem Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PharmChem Inc (1989–2024)
The table below shows the annual net assets of PharmChem Inc from 1989 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.15 Million | -2.64% |
| 2023-12-31 | $2.21 Million | -39.29% |
| 2022-12-31 | $3.63 Million | +27.61% |
| 2021-12-31 | $2.85 Million | -62.07% |
| 2020-12-31 | $7.51 Million | +22.43% |
| 2019-12-31 | $6.13 Million | +19.85% |
| 2018-12-31 | $5.12 Million | +30.90% |
| 2017-12-31 | $3.91 Million | +29.29% |
| 2016-12-31 | $3.02 Million | -63.36% |
| 2003-12-31 | $8.25 Million | -20.33% |
| 2002-12-31 | $10.36 Million | +53.74% |
| 2001-12-31 | $6.74 Million | -55.07% |
| 2000-12-31 | $14.99 Million | +9.48% |
| 1999-12-31 | $13.70 Million | +25.55% |
| 1998-12-31 | $10.91 Million | +7.71% |
| 1997-12-31 | $10.13 Million | -10.26% |
| 1996-12-31 | $11.29 Million | +2.61% |
| 1995-12-31 | $11.00 Million | -38.20% |
| 1994-12-31 | $17.80 Million | +0.56% |
| 1993-12-31 | $17.70 Million | -18.06% |
| 1992-12-31 | $21.60 Million | -4.00% |
| 1991-12-31 | $22.50 Million | +212.50% |
| 1990-12-31 | $7.20 Million | +9.09% |
| 1989-12-31 | $6.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmChem Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 855375400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.62K | 0.22% |
| Other Components | $12.20 Million | 567.70% |
| Total Equity | $2.15 Million | 100.00% |
PharmChem Inc Competitors by Market Cap
The table below lists competitors of PharmChem Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Luz del Sur S.A.A.
LIM:LUSURC1
|
$32.43K |
|
AGI Infra Limited
NSE:AGIIL
|
$32.43K |
|
VH Global Sustainable Energy Opportunities PLC
LSE:GSEO
|
$32.46K |
|
VLID3F
SA:VLID3F
|
$32.46K |
|
General Company For Land Reclamation,Development & Reconstru
EGX:AALR
|
$32.34K |
|
Hansol Technics Co. Ltd.
KQ:004710
|
$32.30K |
|
LS TELCOM - Dusseldorf Stock Exchang
DU:LSX
|
$32.30K |
|
Essentra PLC
LSE:ESNT
|
$32.30K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmChem Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,206,912 to 2,148,615, a change of -58,297 (-2.6%).
- Net income of 1,380,691 contributed positively to equity growth.
- Dividend payments of 1,161,932 reduced retained earnings.
- Share repurchases of 83,321 reduced equity.
- Other factors decreased equity by 193,735.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.38 Million | +64.26% |
| Dividends Paid | $1.16 Million | -54.08% |
| Share Repurchases | $83.32K | -3.88% |
| Other Changes | $-193.74K | -9.02% |
| Total Change | $- | -2.64% |
Book Value vs Market Value Analysis
This analysis compares PharmChem Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.72x to 7.07x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-12-31 | $1.91 | $3.27 | x |
| 1990-12-31 | $1.62 | $3.27 | x |
| 1991-12-31 | $4.37 | $3.27 | x |
| 1992-12-31 | $3.66 | $3.27 | x |
| 1993-12-31 | $3.18 | $3.27 | x |
| 1994-12-31 | $3.56 | $3.27 | x |
| 1995-12-31 | $1.99 | $3.27 | x |
| 1996-12-31 | $1.98 | $3.27 | x |
| 1997-12-31 | $1.71 | $3.27 | x |
| 1998-12-31 | $1.82 | $3.27 | x |
| 1999-12-31 | $2.30 | $3.27 | x |
| 2000-12-31 | $2.47 | $3.27 | x |
| 2001-12-31 | $1.15 | $3.27 | x |
| 2002-12-31 | $1.77 | $3.27 | x |
| 2003-12-31 | $0.00 | $3.27 | x |
| 2016-12-31 | $0.52 | $3.27 | x |
| 2017-12-31 | $0.67 | $3.27 | x |
| 2018-12-31 | $0.87 | $3.27 | x |
| 2019-12-31 | $0.89 | $3.27 | x |
| 2020-12-31 | $1.07 | $3.27 | x |
| 2021-12-31 | $0.43 | $3.27 | x |
| 2022-12-31 | $0.68 | $3.27 | x |
| 2023-12-31 | $0.44 | $3.27 | x |
| 2024-12-31 | $0.46 | $3.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmChem Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 64.26%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.69%
- • Asset Turnover: 2.23x
- • Equity Multiplier: 1.27x
- Recent ROE (64.26%) is above the historical average (5.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -13.64% | -8.74% | 1.07x | 1.45x | $-1.56 Million |
| 1990 | 5.56% | 2.58% | 1.38x | 1.56x | $-320.00K |
| 1991 | 7.56% | 7.05% | 0.89x | 1.20x | $-550.00K |
| 1992 | 10.65% | 8.39% | 0.87x | 1.46x | $140.00K |
| 1993 | -22.03% | -13.45% | 1.00x | 1.64x | $-5.67 Million |
| 1994 | 0.56% | 0.30% | 1.19x | 1.59x | $-1.68 Million |
| 1995 | -61.82% | -17.39% | 1.76x | 2.02x | $-7.90 Million |
| 1996 | 0.41% | 0.11% | 1.92x | 1.90x | $-1.08 Million |
| 1997 | -12.54% | -3.24% | 1.78x | 2.18x | $-2.28 Million |
| 1998 | 5.82% | 1.47% | 1.96x | 2.02x | $-456.00K |
| 1999 | 20.44% | 6.29% | 1.78x | 1.83x | $1.43 Million |
| 2000 | 9.08% | 2.91% | 1.72x | 1.82x | $-138.50K |
| 2001 | -125.79% | -19.27% | 1.54x | 4.23x | $-9.15 Million |
| 2002 | -12.49% | -4.30% | 1.33x | 2.19x | $-2.33 Million |
| 2003 | -26.01% | -8.12% | 1.59x | 2.02x | $-2.97 Million |
| 2016 | 33.58% | 24.36% | 1.15x | 1.19x | $712.92K |
| 2017 | 30.14% | 25.12% | 1.03x | 1.17x | $787.45K |
| 2018 | 30.47% | 30.22% | 0.88x | 1.15x | $1.05 Million |
| 2019 | 28.01% | 31.02% | 0.80x | 1.13x | $1.11 Million |
| 2020 | 26.11% | 29.41% | 0.77x | 1.15x | $1.21 Million |
| 2021 | 65.02% | 29.78% | 1.83x | 1.19x | $1.57 Million |
| 2022 | 23.95% | 14.91% | 1.43x | 1.12x | $506.94K |
| 2023 | 38.29% | 14.06% | 2.17x | 1.25x | $624.41K |
| 2024 | 64.26% | 22.69% | 2.23x | 1.27x | $1.17 Million |
Industry Comparison
This section compares PharmChem Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmChem Inc (PCHM) | $2.15 Million | -13.64% | 0.27x | $32.35K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |